Demonstrating continued revenue growth, operational efficiencies and positive cash flowMOUNTAIN VIEW, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced preliminary unaudited operational and financial results for the fourth quarter and full year ended January 3, 2026. Fourth Quarter 2025 Results ...

Core Insights - Iridex Corporation has announced preliminary unaudited operational and financial results for Q1 2025, indicating a stabilization of the business and improved financial condition following a strategic investment by Novel Inspiration International Co., Ltd [1][3] Financial Performance - Total revenue for Q1 2025 is expected to be between $11.8 million and $12.0 million, consistent with $11.8 million in the same quarter of 2024 [7] - The company sold approximately 13,900 Cyclo G6 probes in Q1 2025, an increase from 13,300 in the prior year quarter [7] - The sales of Cyclo G6 Laser Systems rose to approximately 24 units in Q1 2025, compared to 22 units in the prior year quarter [7] - Cash and cash equivalents as of March 29, 2025, were reported at $7.2 million [7] Strategic Outlook - The company aims to achieve breakeven or better performance at historical revenue levels despite external factors such as changes in tariff policies [3] - An investor call is scheduled for April 16, 2025, to discuss Iridex and Novel's strategic vision for the company [3] Company Overview - Iridex Corporation specializes in developing, manufacturing, and marketing laser-based medical systems and devices for the ophthalmology market, particularly for treating glaucoma and retinal diseases [4] - The company's proprietary MicroPulse® technology offers a differentiated laser treatment for sight-threatening eye conditions [4] - Iridex products are distributed in over 100 countries, primarily through independent distributors [4]